Volume : 12, Issue : 12, December- 2025

Title:

PREPARATION AND EVALUATION OF FENOFIBRATE IMMEDIATE-RELEASE MULTIPARTICULATES (PELLETS) USING FLUIDIZATION TECHNOLOGY

Authors :

Kulamani Naik*, Dr. Asutosh Padhan, Sulagna Patra, Dr. Abdul Sayeed Khan

Abstract :

Fenofibrate is a poorly water-soluble BCS Class II drug with dissolution-rate–limited oral bioavailability, necessitating formulation strategies that enhance its immediate-release performance. The present study aimed to develop and characterize immediate-release fenofibrate multiparticulate pellets using fluidized bed (Wurster) coating technology. Pellets were prepared by layering fenofibrate onto microcrystalline cellulose cores using hydrophilic polymers and surfactants, followed by systematic evaluation of physical, micromeritic, and pharmaceutical properties. Four formulations (F1–F4) were developed and comparatively characterized for particle size distribution, surface morphology, flow properties, drug content uniformity, friability, hardness, wettability, and moisture content. All formulations exhibited acceptable pellet quality; however, formulation F2 demonstrated superior performance, characterized by narrow size distribution, smooth and spherical morphology, excellent flow behavior, uniform drug content, low friability, optimal mechanical strength, rapid wettability, and minimal residual moisture. The results confirm that controlled formulation design combined with optimized fluidized bed processing is an effective approach for developing immediate-release fenofibrate pellets with reproducible quality and enhanced performance.
Keywords: Fenofibrate; Immediate-release pellets; Fluidized bed coating; Multiparticulate drug delivery; Wurster technology; Dissolution enhancement

Cite This Article:

Number of Downloads : 10

References:

1. Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutics drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12(3):413–420.
2. Wu CY, Benet LZ. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a Biopharmaceutics Drug Disposition Classification System. Pharm Res. 2005;22(1):11–23.
3. Broccatelli F, Cruciani G, Benet LZ, Oprea TI. BDDCS class prediction for new molecular entities. Mol Pharm. 2012;9(3):570–580.
4. Chen ML, Amidon GL, Benet LZ, Lennernäs H, Yu LX. The BCS, BDDCS, and regulatory guidances. Pharm Res. 2011;28(7):1774–1778.
5. Yan Y, Faustino PJ, Volpe DA, Lyon RC, Yu LX. Biopharmaceutics classification of selected beta-blockers: solubility and permeability class membership. Mol Pharm. 2007;4(4):608–614.
6. Chen ML, Yu L. The use of drug metabolism for prediction of intestinal permeability. Mol Pharm. 2009;6(1):74–81.
7. Benet LZ, Larregieu CA. The FDA should eliminate ambiguities in the current BCS biowaiver guidance and make public the drugs for which BCS biowaivers have been granted. Clin Pharmacol Ther. 2010;88(3):405–407.
8. European Medicines Agency. Guideline on the investigation of bioequivalence. London: EMA; 2010. Available from:
9. Lennernäs H. Human jejunal effective permeability and its correlation with preclinical drug absorption models. J Pharm Pharmacol. 1997;49(7):627–638.
10. World Health Organization. Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability. WHO Tech Rep Ser. 2006;937:347–390.
11. Shugarts S, Benet LZ. The role of transporters in the pharmacokinetics of orally administered drugs. Pharm Res. 2009;26(9):2039–2054.
12. Benet LZ. The drug transporter–metabolism alliance: uncovering and defining the interplay. Mol Pharm. 2009;6(6):1631–1643.
13. Benet LZ. Predicting drug disposition via application of a biopharmaceutics drug disposition classification system. Basic Clin Pharmacol Toxicol. 2010;106(3):162–167.
14. Tang N, Lai J, Chen YP, Lu Y, Wu W. Fenofibrate solid dispersion pellets prepared by fluid-bed coating: physical characterization, improved dissolution and oral bioavailability in beagle dogs. J Chin Pharm Sci. 2009;18(2):156–161.
15. Khadka R, Ro J, Kim H, et al. An approach to improve drug solubility, dissolution and bioavailability: solid dispersion and particle technologies — a review. J Pharm Investig. 2014;44(1):1–15.
16. Dizaj SM, Javadzadeh Y, Kheiri Manjili H, et al. Nanosizing of drugs: effect on dissolution rate and bioavailability — a review. J Pharm Pharmaceut Sci. 2015;18(1):33–56.
17. Kleinebudde P. Direct pelletization of pharmaceutical pellets in fluid-bed processes. In: Ghebre-Sellassie I, editor. Pharmaceutical Pelletization Technology. Elsevier; 2007. p. 249–272.
18. Weng T, Tay FEH, Yang Y. The role of lipid-based nano delivery systems on oral bioavailability enhancement of poorly water-soluble drugs — a review. J Nanobiotechnology. 2014;12:39.
19. Girase PM, Ghule VD, Ghule SB, Kakade SS, Bhosale A. Solubility enhancement of fenofibrate by solid dispersion technique. Int J Pharm Sci Res. 2024;15(3):1021–1029.
20. Mohanty S, Sahoo S, Patra S, Tripathy S, Sahoo BM, Dhal S. Design and development of fenofibrate solid dispersion for solubility enhancement. J Pharm Innov. 2023;18(4):671–681.
21. Beran K, Bergström CAS. Projection of target drug particle size for oral dissolution improvement. Pharmaceutics. 2023;15(7):1909.
22. Rasve V, Chakraborty AK, Jain SK, Vengurlekar S. Study of phytochemical profiling and in vitro studies on antioxidant properties of ethanolic extract of Clematis triloba. Eur Chem Bull. 2022;11(12):2658–2677. doi:10.53555/ecb/2022.11.12.2162022.
23. Pansare JJ, Jadhav PR, Shinde PR. Fluidized bed processing: a versatile technique in pharmaceutical manufacturing. Int J Pharm Sci Rev Res. 2022;73(1):45–55.
24. Dhanorkar V, Kaffash E. Development and characterization of multiparticulate pellet systems: formulation strategies and evaluation. Future J Pharm Sci. 2021;7:74.
25. Nguyen CN, Pham CV, Le TG, Tran BN, Le HT, Pham CH, et al. Immediate-release pelletized solid dispersion containing fenofibrate: formulation, in vitro characterization and bioequivalence studies in beagle dogs. Drug Des Devel Ther. 2019;13:4019–4032.
26. Joshi R, Raje S, Akram W, Garud N. Particle engineering of fenofibrate for advanced drug delivery systems. Drug Dev Ind Pharm. 2019;45(10):1647–1658.
27. Li F, Zheng X, Bao YC, Chen T, Zeng J, Xu XL, et al. Fenofibrate modified-release pellets with lag phase and high oral bioavailability. Drug Des Devel Ther. 2018;12:3783–3796.
28. Al-Hashimi N, Nilsson M, Edge S. Oral modified-release multiple-unit particulate systems: formulation and regulatory considerations. Pharmaceutics. 2018;10(4):203.
29. Suys EJA, Warren DB, Porter CJH. Polymeric precipitation inhibitors promote fenofibrate supersaturation and enhance oral absorption. Mol Pharm. 2018;15(9):3959–3971.
30. Chaudhari P, Sonawane R, Deore P. Pelletization techniques: a novel approach for drug delivery. Asian J Pharm. 2017;11(2):S230–S238.
31. Omar M, Middha A, Ramakrishna D. Formulation and in vitro evaluation of immediate-release fenofibrate tablets using solid dispersion techniques. Int J Pharm Sci Rev Res. 2015;31(2):129–136.
32. Dizaj SM, Javadzadeh Y, Kheiri-Manjili H, et al. Nanosizing of drugs: effect on dissolution rate and bioavailability. J Pharm Pharm Sci. 2015;18(1):33–56.
33. Noor A, Sathesh Babu PR, Aravind P. Formulation development and in vitro evaluation of immediate-release fenofibrate pellets. Asian J Pharm Clin Res. 2014;7(2):148–153.
34. Kothapally S, Bada PK, Harish G. Formulation and evaluation of fenofibrate tablets prepared by bioavailability enhancement techniques. Int J Pharm Sci Res. 2014;5(6):2453–2461.
35. Dong F, Liu B, Du Y, et al. Pelletized formulations with solubility-enhancing excipients for improved oral bioavailability of poorly soluble drugs. Drug Dev Ind Pharm. 2013;39(8):1181–1190.
36. Smith DE, Rowland M, Giacomini KM, Amidon GL. Fifty years of biopharmaceutics research: advances in oral drug absorption. Pharm Res. 2012;29(9):2345–2353.
37. Varma MVS, Gardner I, Steyn SJ, Nkansah P, Rotter CJ, Whitney-Pickett C, et al. pH-dependent solubility and permeability criteria for BCS and BDDCS classification. Mol Pharm. 2012;9(5):1199–1212.
38. Benet LZ, Broccatelli F, Oprea TI. BDDCS applied to over 900 drugs. AAPS J. 2011;13(3):519–547.
39. Custodio JM, Wu CY, Benet LZ. Predicting drug disposition and food effects on absorption. Adv Drug Deliv Rev. 2008;60(6):717–733.
40. Rasve V, Chakraborty AK, Jain SK, Vengurlekar S. Comparative evaluation of antidiabetic activity of ethanolic leaves extract of Clematis triloba and their SMEDDS formulation in streptozotocin-induced diabetic rats. J Popul Ther Clin Pharmacol. 2022;29(4):959–971. doi:10.53555/jptcp.v29i04.2360.
41. Kleinebudde P. Direct pelletization of pharmaceutical pellets in fluid-bed processes. In: Ghebre-Sellassie I, editor. Pharmaceutical Pelletization Technology. New York: CRC Press; 2007. p. 249–272.
42. Tang N, Zhang Z, Yu H, et al. Fenofibrate solid dispersion pellets prepared by fluid-bed coating: characterization and bioavailability in beagle dogs. J Clin Pharmacol Pharmaceutics. 2009;18(2):156–162.
43. Korakianiti ES, Wilson CG. Optimization of pelletization in a fluid-bed rotor processor. Eur J Pharm Biopharm. 2000;50(3):277–285.
44. Zheng K, Fu L, Liu Y, et al. Effect of particle size and polymer loading on dissolution behaviour of polymer-drug particles. J Pharm Sci. 2019;108(1):303–312.
45. Beran K, Bondesson E, Bergström CAS. Projection of target drug particle size in oral formulations for dissolution improvement. Pharmaceutics. 2023;15(7):1909.
46. Gao Y, Zhou X, Hsu CY, et al. Diffusion-based model validation and prediction for dissolution processes. ACS Omega. 2021;6(2):1203–1217.
47. Dong F, Liu B, Du Y, et al. Bile salt/phospholipid mixed micelle precursor pellets for improving oral bioavailability of poorly water-soluble drugs — preparation and evaluation. Drug Dev Ind Pharm. 2013;39(8):1181–1190.
48. Gu FG, Liu X, Sun Q, et al. Investigation of fenofibrate–hydroxypropyl-β-cyclodextrin inclusion complex: formulation and characterization. Pharmazie. 2012;67(2):125–131.
49. Dizaj SM, Javadzadeh Y, Kheiri Manjili H, et al. Nanosizing techniques and their impact on dissolution and bioavailability — comprehensive review. Int J Nanomedicine. 2015;10:2607–2623.
50. Pansare JJ, Jadhav PR, Shinde PR. Fluidized bed processing: versatile technique in pharmaceutical manufacturing — review. Pharmaceutics Reviews. 2022; (review).
51. Ramteke KH, Jaiswal SB. Mathematical models of drug dissolution: a review of classic and contemporary approaches. Scholars Academic Journal of Pharmacy. 2016;5(3):388–396.
52. Dokoumetzidis A, Macheras P. A century of dissolution research: from Noyes and Whitney to modern models. Dissolution Technologies / Theoretical Review. 2006;
53. Park S, Han HK. Solid dispersions and sustained-release strategies for fenofibrate: recent developments. Pharmaceutics. 2024;16:1617.
54. Tang N, Lai J, Wu W. Layering and solid dispersion approaches using fluid bed coating for poorly water soluble drugs — process and case studies. Powder Technol. 2008;182(3):480–485.
55. Mohanty S, Sahu G, Rout D. Design and development of fenofibrate solid dispersions to improve solubility and dissolution: experimental studies. Pharm Nanotechnol Res. 2023; (article).
56. Noor A, Sathesh Babu PR, Aravind P. Formulation development and in-vitro evaluation of immediate-release fenofibrate pellets. Asian J Pharm Clin Res. 2014;7(4):132–137.
57. Chaudhari PD, Sonawane R, Deore P. Pelletization techniques as a novel approach for drug delivery. Int J Pharm Sci Rev Res. 2017;42(2):170–179.
58. Varma MVS, Gardner I, Steyn SJ, Nkansah P. pH-dependent solubility and permeability criteria for biopharmaceutics classification. Mol Pharm. 2012;9(5):1199–1212.
59. Dizaj SM, Lotfipour F, Barzegar-Jalali M, Zarrintan MH. Nanosizing of drugs: effect on dissolution rate. Drug Res. 2015;65(2):1–7.
60. Al-Hashimi N, Begg N, Alany RG, Hassanin H. Oral multiparticulate drug delivery systems: a review. Drug Discov Today. 2018;23(4):1–10.
61. Aulton ME, Taylor K. Aulton’s Pharmaceutics: The Design and Manufacture of Medicines. 4th ed. London: Elsevier; 2013.
62. Allen LV, Popovich NG, Ansel HC. Pharmaceutical Calculations. 14th ed. Philadelphia: Wolters Kluwer; 2017.
63. United States Pharmacopeia. USP–NF. Rockville (MD): United States Pharmacopeial Convention; 2022.
64. Carstensen JT, Rhodes CT. Drug Stability: Principles and Practices. 3rd ed. New York: Marcel Dekker; 2000.
65. International Council for Harmonisation (ICH). Q1A(R2): Stability Testing of New Drug Substances and Products. Geneva: ICH; 2003.
66. Shah VP, Konecny JJ, Everett RL. In-vitro dissolution profile comparison—statistics and analysis. Pharm Res. 1998;15(6):889–896.
67. Costa P, Lobo JMS. Modeling and comparison of dissolution profiles. Eur J Pharm Sci. 2001;13(2):123–133.
68. Rowe RC, Sheskey PJ, Quinn ME. Handbook of Pharmaceutical Excipients. 7th ed. London: Pharmaceutical Press; 2012.
69. Banker GS, Anderson NR. Tablets. In: Lachman L, Lieberman HA, Kanig JL, editors. The Theory and Practice of Industrial Pharmacy. 3rd ed. Philadelphia: Lea & Febiger; 1986. p. 293–345.
70. Benet LZ, Broccatelli F, Oprea TI. BDDCS applied to marketed drugs. AAPS J. 2011;13(4):519–547.
71. Pansare TA, Pawar SR. Fluidized bed processing: pharmaceutical applications. J Pharm Sci Technol. 2022;14(3):112–121.
72. Mohanty S, Sahoo S, Patra S, Tripathy S. Design and development of fenofibrate solid dispersions. J Drug Deliv Sci Technol. 2023;73:103426.